Janssen Pharmaceutica Products, LP

Study: REMINYL may reduce specific behavioral symptoms in Alzheimer patients

Published in Drug Law Weekly, May 18th, 2004

New data published in the March issue of the American Journal of Psychiatry is the first to suggest that treatment with REMINYL (galantamine hydrobromide) may reduce specific behavioral symptoms in patients with mild-to-moderate Alzheimer disease, which may contribute to a reduction in caregiver distress.

The study had three key findings: patients who exhibited behavioral disturbances at the start of the study experienced robust reductions in symptoms; patients who did not have behavioral disturbances showed less emergence of symptoms; and, the reduction in behavioral-related caregiver distress was statistically significant.

The findings from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry